Eli Lilly is preparing a phase 2 trial for VERVE-102, a one-time gene editor acquired from Verve Therapeutics.
-
Eli Lilly is preparing a phase 2 trial for VERVE-102, a one-time gene editor acquired from Verve Therapeutics. The highest dose cut LDL cholesterol by 62% in patients, a reduction sustained for up to 18 months across 35 participants.
The treatment permanently switches off PCSK9, a cholesterol-producing gene, using base editing that flips a single DNA letter without breaking the double helix.
#news #health #medicine #cholesterol #GeneTherapy #GeneEditing
-
T #medicine shared this topic
-
Eli Lilly is preparing a phase 2 trial for VERVE-102, a one-time gene editor acquired from Verve Therapeutics. The highest dose cut LDL cholesterol by 62% in patients, a reduction sustained for up to 18 months across 35 participants.
The treatment permanently switches off PCSK9, a cholesterol-producing gene, using base editing that flips a single DNA letter without breaking the double helix.
#news #health #medicine #cholesterol #GeneTherapy #GeneEditing
Just Me
I'm a little nervous about side effectsThere are roughly 3 billion basepairs in the human genome, and we know that maybe 10% are critical, in that an edit would have some effect
so this base editor has to have an error rate of ~~ < 1 in 300 million
which is unheard of for a chemical reaction
not sure this is real or not, but this sort of problem has gotten a LOT Of discussion among scientists
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better đź’—
Register Login